Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
Autohomologous Immunotherapy, often called AHIT, is a treatment method that uses a patient’s own immune cells or biological material to help fight disease. The term "autohomologous" means the material comes from the same person receiving the treatment, not from a donor. In practice, immune cells or blood components are collected from the patient, sometimes processed or activated outside the body, and then returned to help the immune system better recognize and attack harmful cells like cancer cells. Some versions of AHIT involve treating the material with ozone, a form of oxygen therapy, to stimulate the immune system.
This approach aims to boost the body’s natural defenses rather than directly killing cancer cells with drugs or radiation. It is different from standard cancer immunotherapies like checkpoint inhibitors or CAR-T cell therapy, which have more established roles and scientific support in cancer care.
AHIT is part of a broader group of treatments called immunotherapies, which work by supporting the immune system’s ability to fight cancer. Unlike chemotherapy or radiation, which attack cancer cells directly, AHIT tries to strengthen the immune system’s natural response. Because the cells used come from the patient, there is usually a lower risk of rejection or serious immune reactions compared to treatments using donor cells.
However, AHIT is not widely used in mainstream cancer care and is often considered experimental or complementary. It may be offered in clinical trials or specialized treatment plans when other treatments are not enough or to support the immune system. Patients should understand that AHIT is not a standard treatment and may not be suitable for everyone.
Patients might hear about AHIT during discussions of immunotherapy options or when reviewing treatment plans that include personalized immune-based therapies. The term might appear in medical records, clinical trial descriptions, or alternative therapy literature. Some versions of AHIT involve processing the patient’s biological material with ozone, which is not part of standard cancer immunotherapy and is more common in complementary or alternative medicine.
Because of this, AHIT may be mentioned in contexts outside mainstream oncology. It is important for patients to ask their care team what AHIT means in their specific case, how it works, and what to expect from the treatment.
AHIT should not be confused with other immune-related conditions or treatments that have similar abbreviations. For example, autoimmune heparin-induced thrombocytopenia (aHIT) is a rare immune reaction affecting blood platelets and is unrelated to autohomologous immunotherapy.
Additionally, AHIT is different from well-known cancer immunotherapies like checkpoint inhibitors or CAR-T cell therapy, which have more established roles in cancer treatment. Understanding that AHIT uses the patient’s own cells or material helps set realistic expectations about its benefits and risks.
If AHIT is mentioned in your care, consider asking your healthcare providers: What is the goal of AHIT in my treatment? What evidence supports its use? Are there any risks or side effects? How does it fit with my current treatment plan? Are there clinical trials or other options available?
Reading about AHIT alone can be confusing. It is best understood as a distinct approach within oxidative or alternative therapies rather than a mainstream cancer immunotherapy. Because AHIT is not part of conventional cancer care, it should not be assumed to have the same benefits or risks as approved immunotherapies.
Always discuss any new or unfamiliar treatments with your oncology team to understand how they relate to your overall care.
This information about Autohomologous Immunotherapy is educational and does not replace personalized medical advice. Each patient’s situation is unique, and treatment decisions should be made with the guidance of healthcare professionals.
If you hear about AHIT in your care, the next sensible step is to discuss it openly with your doctor or nurse. Ask how it might apply to your treatment, what to expect, and whether there are clinical trials or other options available. This will help you understand your care plan and feel more confident in your treatment journey.
Public source information used for this glossary entry includes: